IL326852A - תכשירים להשגת רמות מינון יעילות של מעכבי mtor - Google Patents

תכשירים להשגת רמות מינון יעילות של מעכבי mtor

Info

Publication number
IL326852A
IL326852A IL326852A IL32685226A IL326852A IL 326852 A IL326852 A IL 326852A IL 326852 A IL326852 A IL 326852A IL 32685226 A IL32685226 A IL 32685226A IL 326852 A IL326852 A IL 326852A
Authority
IL
Israel
Prior art keywords
compositions
effective dose
dose levels
mtor inhibitors
achieving effective
Prior art date
Application number
IL326852A
Other languages
English (en)
Inventor
Trevor Klee
Original Assignee
Trevor Klee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevor Klee filed Critical Trevor Klee
Publication of IL326852A publication Critical patent/IL326852A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL326852A 2023-09-01 2024-08-30 תכשירים להשגת רמות מינון יעילות של מעכבי mtor IL326852A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363580027P 2023-09-01 2023-09-01
PCT/US2024/044577 WO2025049843A1 (en) 2023-09-01 2024-08-30 Compositions for achieving effective dose levels of mtor inhibitors

Publications (1)

Publication Number Publication Date
IL326852A true IL326852A (he) 2026-04-01

Family

ID=94820306

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326852A IL326852A (he) 2023-09-01 2024-08-30 תכשירים להשגת רמות מינון יעילות של מעכבי mtor

Country Status (5)

Country Link
CN (1) CN121772919A (he)
AU (1) AU2024331788A1 (he)
IL (1) IL326852A (he)
MX (1) MX2026002265A (he)
WO (1) WO2025049843A1 (he)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20170354636A1 (en) * 2015-02-28 2017-12-14 Sequoia Pharmaceuticals, Inc. Methods for inhibiting tumors and drug resistance
US11304954B2 (en) * 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
UY38247A (es) * 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación

Also Published As

Publication number Publication date
AU2024331788A1 (en) 2026-02-26
CN121772919A (zh) 2026-03-31
WO2025049843A1 (en) 2025-03-06
MX2026002265A (es) 2026-04-01

Similar Documents

Publication Publication Date Title
IL318748A (he) הרכבים ושיטות לעיכוב kras
IL317985A (he) תכשירים פרמצבטיים הכוללים מעכבי הליקס של wrn
CR20240382A (es) ANÁLOGOS DE RAPAMICINA A C40, C28 Y C32 COMO INHIBIDORES DE MTOR (Divisional 2020-578)
IL317988A (he) תכשירים פרמצבטיים הכוללים מעכבי הליקס של
IL317736A (he) תרכובות כמעכבות של axl
IL291453A (he) צורות מינון עבור מעכבי tyk2
IL320739A (he) מעכבי rock2
EP4448514A4 (en) TYK2 INHIBITORS AND ASSOCIATED COMPOSITIONS AND PROCESSES
PL4284511T3 (pl) Azachinoliny jako inhibitory cd38
IL320892A (he) תכשירי רוקחות לטיפול או מניעה של עמילואידוזיס בתיווך טרנסתירטין
IL314824A (he) פורמולציה משולבת של סדאזורידין
IL325596A (he) תכשירי רוקחות למעכבים של nek7 קינאז
IL317433A (he) תרכובות לטיפול ב- xlmtm
SI4214210T1 (sl) Spojine in sestavki kot zaviralci sppl2a
KR102434191B9 (ko) 화재확산방지를 위한 보호 외함
IL316843A (he) תרכובות ושיטות לעיכוב ביטול של snca
GB202208022D0 (en) Therapeutic compounds and compositions
IL313703A (he) תכשירים לטיפול בדלקת
CA3297265A1 (en) Pharmaceutical compositions for inhibitors of nek7 kinase
IL325331A (he) מעכבים של tyk2, תכשירים המכילים אותם ושימושיהם
CA3276315A1 (en) Composition for preventing or treating side effects of cholinesterase inhibitors
CA3293535A1 (en) Inhibitors of tyk2
CA3273897A1 (en) Inhibitors of tyk2
GB202501591D0 (en) Compositions for treatment of ear conditions
CA3298237A1 (en) Methods of treating difluoropropene compositions